Works matching IS 14764598 AND DT 2025 AND VI 24 AND IP 1

Results: 121
    1
    2
    3

    The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02320-y
    By:
    • Atas, Emine;
    • Berchtold, Kerstin;
    • Schlederer, Michaela;
    • Prodinger, Sophie;
    • Sternberg, Felix;
    • Pucci, Perla;
    • Steel, Christopher;
    • Matthews, Jamie D.;
    • James, Emily R.;
    • Philippe, Cécile;
    • Trachtová, Karolína;
    • Moazzami, Ali A.;
    • Artamonova, Nastasiia;
    • Melchior, Felix;
    • Redmer, Torben;
    • Timelthaler, Gerald;
    • Pohl, Elena E.;
    • Turner, Suzanne D.;
    • Heidegger, Isabel;
    • Krueger, Marcus
    Publication type:
    Article
    4
    5

    Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02324-8
    By:
    • Fukuda, Ryo;
    • Fujiwara, Yukio;
    • Maeda, Hitoshi;
    • Pan, Cheng;
    • Minayoshi, Yuki;
    • Yano, Hiromu;
    • Mizuta, Yuki;
    • Takano, Mei;
    • Yamada, Rin;
    • Saito, Yoichi;
    • Hirata, Kenshiro;
    • Imoto, Shuhei;
    • Yamasaki, Keishi;
    • Oniki, Kentaro;
    • Saruwatari, Junji;
    • Otagiri, Masaki;
    • Watanabe, Hiroshi;
    • Komohara, Yoshihiro;
    • Maruyama, Toru
    Publication type:
    Article
    6
    7

    Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-024-02191-9
    By:
    • Jenkins, Benjamin H.;
    • Tracy, Ian;
    • Rodrigues, Maria Fernanda S. D.;
    • Smith, Melanie J. L.;
    • Martinez, Begoña R.;
    • Edmond, Mark;
    • Mahadevan, Sangeetha;
    • Rao, Anjali;
    • Zong, Hailing;
    • Liu, Kai;
    • Aggarwal, Abhishek;
    • Li, Li;
    • Diehl, Lauri;
    • King, Emma V.;
    • Bates, Jamie G.;
    • Hanley, Christopher J.;
    • Thomas, Gareth J.
    Publication type:
    Article
    8
    9

    Therapy-induced senescence is a transient drug resistance mechanism in breast cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02310-0
    By:
    • Bajtai, Eszter;
    • Kiss, Csaba;
    • Bakos, Éva;
    • Langó, Tamás;
    • Lovrics, Anna;
    • Schád, Éva;
    • Tisza, Viktória;
    • Hegedűs, Károly;
    • Fürjes, Péter;
    • Szabó, Zoltán;
    • Tusnády, Gábor E.;
    • Szakács, Gergely;
    • Tantos, Ágnes;
    • Spisák, Sándor;
    • Tóvári, József;
    • Füredi, András
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02312-y
    By:
    • Umeda, Hibiki;
    • Shigeyasu, Kunitoshi;
    • Takahashi, Toshiaki;
    • Moriwake, Kazuya;
    • Kondo, Yoshitaka;
    • Yoshida, Kazuhiro;
    • Takeda, Sho;
    • Yano, Shuya;
    • Matsumi, Yuki;
    • Kishimoto, Hiroyuki;
    • Fuji, Tomokazu;
    • Yasui, Kazuya;
    • Yamamoto, Hideki;
    • Takagi, Kosei;
    • Kayano, Masashi;
    • Michiue, Hiroyuki;
    • Nakamura, Keiichiro;
    • Mori, Yoshiko;
    • Teraishi, Fuminori;
    • Tazawa, Hiroshi
    Publication type:
    Article
    21
    22

    BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02319-5
    By:
    • Fu, Lingyi;
    • Li, Shuo;
    • Mei, Jie;
    • Li, Ziteng;
    • Yang, Xia;
    • Zheng, Chengyou;
    • Li, Nai;
    • Lin, Yansong;
    • Cao, Chao;
    • Liu, Lixuan;
    • Huang, Liyun;
    • Shen, Xiujiao;
    • Huang, Yuhua;
    • Yun, Jingping
    Publication type:
    Article
    23
    24
    25

    Caveolin-1: an ambiguous entity in breast cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02297-8
    By:
    • Chintalaramulu, Naveen;
    • Singh, Dhirendra Pratap;
    • Sapkota, Biplov;
    • Raman, Dayanidhi;
    • Alahari, Suresh;
    • Francis, Joseph
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34

    Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02275-0
    By:
    • Korbie, Darren;
    • Stirzaker, Clare;
    • Gluz, Oleg;
    • zu Eulenburg, Christine;
    • Nitz, Ulrike;
    • Christgen, Matthias;
    • Kuemmel, Sherko;
    • Grischke, Eva-Maria;
    • Forstbauer, Helmut;
    • Braun, Michael;
    • Warm, Mathias;
    • Hackmann, John;
    • Uleer, Christoph;
    • Aktas, Bahriye;
    • Schumacher, Claudia;
    • Wuerstlein, Rachel;
    • Pelz, Enrico;
    • Kreipe, Hans Heinrich;
    • Clark, Susan J.;
    • Trau, Matt
    Publication type:
    Article
    35
    36

    EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02290-1
    By:
    • Zhou, Jiefu;
    • He, Min;
    • Zhao, Qiong;
    • Shi, Enxian;
    • Wang, Hairong;
    • Ponkshe, Vaidehi;
    • Song, Jiahang;
    • Wu, Zhengquan;
    • Ji, Dongmei;
    • Kranz, Gisela;
    • Tscherne, Anna;
    • Schwenk-Zieger, Sabina;
    • Razak, Nilofer Abdul;
    • Hess, Julia;
    • Belka, Claus;
    • Zitzelsberger, Horst;
    • Ourailidis, Iordanis;
    • Stögbauer, Fabian;
    • Boxberg, Melanie;
    • Budczies, Jan
    Publication type:
    Article
    37
    38
    39
    40
    41
    42

    DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02291-0
    By:
    • Morris, Benjamin B.;
    • Heeke, Simon;
    • Xi, Yuanxin;
    • Diao, Lixia;
    • Wang, Qi;
    • Rocha, Pedro;
    • Arriola, Edurne;
    • Lee, Myung Chang;
    • Tyson, Darren R.;
    • Concannon, Kyle;
    • Ramkumar, Kavya;
    • Stewart, C. Allison;
    • Cardnell, Robert J.;
    • Wang, Runsheng;
    • Quaranta, Vito;
    • Wang, Jing;
    • Heymach, John V.;
    • Nabet, Barzin Y.;
    • Shames, David S.;
    • Gay, Carl M.
    Publication type:
    Article
    43
    44
    45
    46
    47

    Autophagy in tumor immune escape and immunotherapy.

    Published in:
    Molecular Cancer, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12943-025-02277-y
    By:
    • Wang, Huan;
    • Sun, Peng;
    • Yuan, Xijing;
    • Xu, Zhiyong;
    • Jiang, Xinyuan;
    • Xiao, Mingshu;
    • Yao, Xin;
    • Shi, Yueli
    Publication type:
    Article
    48
    49
    50